Eli Lilly Begins Human Trial of Antibody Against Covid-19
June 01 2020 - 7:13AM
Dow Jones News
By Matt Grossman
Eli Lilly and Co. said Monday that it has begun human trials of
an antibody treatment for Covid-19.
The Indianapolis-based pharmaceutical company developed the
treatment, called LY-CoV5555, with AbCellera. It is based on
antibodies found in the blood of a recovered Covid-19 patient.
Phase 1 trials are taking place at medical centers including in
New York City and Los Angeles. If the trials show that the
treatment is safe, Eli Lilly plans additional trials both in
non-hospitalized patients and in people who are not sick, to test
the medicine's value as a preventative.
If the trials are successful, the company said it hopes to have
several hundred thousand doses available by the end of the
year.
Write to Matt Grossman at matt.grossman@wsj.com
(END) Dow Jones Newswires
June 01, 2020 06:58 ET (10:58 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.